- Investing Ideas
- /
- Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
5
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
5 companies
Vitrolife
Market Cap: SEK 17.5b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 129.10
7D
-2.1%
1Y
-49.4%
Bonesupport Holding
Market Cap: SEK 19.0b
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
BONEX
SEK 288.80
7D
-6.6%
1Y
-3.7%
BioGaia
Market Cap: SEK 10.9b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 108.20
7D
-0.3%
1Y
-3.5%
Genovis AB (publ.)
Market Cap: SEK 1.5b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 22.65
7D
-1.5%
1Y
-19.5%
AddLife
Market Cap: SEK 22.0b
Provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries.
ALIF B
SEK 180.60
7D
-5.5%
1Y
11.5%